Loading…
Loading…
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday, August 5, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of th.
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
California Public Employees Retirement System increased its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 5.9% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,289 shares of the biotechnology company's stock after acquiring an additional
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved.
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of th.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for UTHR and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.